Success Metrics

Clinical Success Rate
86.7%

Based on 26 completed trials

Completion Rate
87%(26/30)
Active Trials
13(24%)
Results Posted
88%(23 trials)
Terminated
4(7%)

Phase Distribution

Ph phase_2
25
46%
Ph phase_4
7
13%
Ph phase_1
8
15%
Ph phase_3
8
15%

Phase Distribution

8

Early Stage

25

Mid Stage

15

Late Stage

Phase Distribution48 total trials
Phase 1Safety & dosage
8(16.7%)
Phase 2Efficacy & side effects
25(52.1%)
Phase 3Large-scale testing
8(16.7%)
Phase 4Post-market surveillance
7(14.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.9%

26 of 31 finished

Non-Completion Rate

16.1%

5 ended early

Currently Active

13

trials recruiting

Total Trials

54

all time

Status Distribution
Active(15)
Completed(26)
Terminated(5)
Other(8)

Detailed Status

Completed26
Recruiting12
unknown8
Terminated4
Not yet recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
54
Active
13
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Phase 18 (16.7%)
Phase 225 (52.1%)
Phase 38 (16.7%)
Phase 47 (14.6%)

Trials by Status

not_yet_recruiting24%
terminated47%
withdrawn12%
recruiting1222%
active_not_recruiting12%
completed2648%
unknown815%

Recent Activity

Clinical Trials (54)

Showing 20 of 54 trialsScroll for more
NCT06576271Phase 1

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

Recruiting
NCT04097561Phase 1

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Recruiting
NCT03207958Phase 1

Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation

Completed
NCT03844061Phase 2

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Recruiting
NCT07340463Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting
NCT06572384Phase 3

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
NCT03949855Phase 2

Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
NCT05878717Phase 2

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Recruiting
NCT06716606Phase 3

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

Recruiting
NCT05917288Phase 1

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

Completed
NCT04179032Phase 2

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

Active Not Recruiting
NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not Yet Recruiting
NCT04908865Phase 4

Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)

Completed
NCT01532310

Belimumab (BENLYSTA®) Pregnancy Registry

Completed
NCT04515719Phase 4

Efficacy and Safety of Belimumab in SLE Patients

Completed
NCT03312907Phase 3

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Completed
NCT05154734Phase 1

Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders

Completed
NCT04629144Phase 2

Efficacy and Safety of Belimumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Compared to Placebo. TRIBECA STUDY (Treatment nd BElimumab in Cryoglobulinemia Associated Vasculitis)

Recruiting
NCT04570306

Transcriptional and Immune Parameters of Response to Belimumab

Completed
NCT06410833Phase 4

Belimumab After Rituximab in Resistant Primary Juvenile SS

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
54